PolarCool is growing in German elite ice hockey – Eisbären Berlin signs an agreement
The med-tech company PolarCool AB (publ) continues its successful expansion of PolarCap® System in European ice hockey. The company has signed a 3-year agreement with the German multiple champion team Eisbären Berlin for the use of the PolarCap® System.
PolarCool develops and markets the product PolarCap®, which alleviates the effects of concussion. The primary users of PolarCap® include sports clubs, organizations, and facilities in contact sports such as ice hockey, rugby, football and handball, but also other sports with an increased risk of concussion.
PolarCool has previously established strategic collaborations in German ice hockey with both Adler Mannheim and Dresdner Eislöwen. The agreement with Eisbären Berlin marks yet another important step for the Company on the international ice hockey market. Eisbären Berlin plays in the German top league DEL and is a nine-time champion.
Eisbären Berlin Sportphysiotherapeut Andre Kreidler comments:
-We are really looking forward to adding the PolarCap® System to our routines for acute concussion management. Our priority is to give our players the best possible conditions to alleviate the effects of concussions.
PolarCool CEO Erik Andersson comments:
-We are very pleased that yet another German ice hockey club chooses to sign an agreement for the use of the PolarCap® System. We notice an increased interest in providing PolarCap® System and foresee that awareness of our treatment method will increase as more clubs sign contracts.
The agreement is in line with PolarCool's overall strategy to introduce the treatment to the international ice hockey market. The agreement is strategically important, even if the financial impact of individual agreements is limited.
For more information
Erik Andersson – CEO PolarCool AB (publ)
+46 - 738 60 57 00
E-mail: [email protected]
About PolarCool AB (publ)
PolarCool AB (publ) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.
Stayble Therapeutics presents at Financial Stockholm's investor meeting on September 25, 2023
On Monday, September 25, Stayble will be one of several companies presenting at Financial Stockholm's investor meeting at Scandic Anglais in Stockholm. At 17:50, Stayble's CEO, Andreas Gerward, will share insights about the Company's latest progress, future plans, and how Stayble is work...
Stayble Therapeutics presenterar på Financial Stockholms investerarträff den 25 september 2023
Måndagen den 25 september kommer Stayble vara ett av flera bolag som presenterar vid Financial Stockholms investerarträff på Scandic Anglais i Stockholm. Klockan 17:50 kommer Staybles VD, Andreas Gerward, att dela insikter om Bolagets senaste framsteg, framtida planer och hur Stayble jobbar mot att...
Delrapport från klinisk studie: ColdZyme minskar signifikant mängden rhinovirus samt symptom på halsont
De första resultaten från en pågående oberoende klinisk studie vid universitetet i Kent, Storbritannien, visar att ColdZyme® signifikant minskar mängden rhinovirus, den vanligaste orsaken till förkylning. Dessutom upplevde deltagare som använde ColdZyme sign...
Interim report from clinical study: ColdZyme significantly reduces rhinovirus viral load and symptoms of sore throat
The first results from an ongoing independent clinical study at the University of Kent, UK, show that ColdZyme® significantly reduces the viral load of rhinovirus, the predominant cause of the common cold. Additionally, participants who used ColdZyme experienced significantly less severe sore th...